FG’s pharma tax incentives fail to curb soaring medicine prices

…Manufacturers seek policy continuity for impact
Tax waivers and incentives approved for Nigeria’s pharmaceutical sector have yet to translate into more affordable medicines for citizens or an increase in domestic production, as the country remains heavily dependent on imported medicines and healthcare products.
The latest data from the Federal Ministry of Health and Social Welfare show that locally manufactured products remain low, accounting for only 20 percent of the market, compared with 80 percent for imported products. This is despite the market’s estimated value of between $4 billion and $6 billion.
In 2024, President Bola Tinubu signed an Executive Order removing tariffs, excise duties and Value Added Tax on selected pharmaceutical machinery and raw materials.
The incentive, which took effect on October 11, 2024, for a two-year period, was introduced to lower manufacturers’ production costs, encourage investment in local factories and ultimately make medicines more affordable.
This followed the exit of several multinational pharmaceutical companies from Nigeria, which heightened concerns about the country’s dependence on imported medicines and production inputs.
Consequently, the Federal Government approved more than N24 billion in tax waivers for 75 pharmaceutical manufacturers between January 2025 and June 2026. The government also reported a 12 percent reduction in production costs under the Executive Order.
However, the data show that local manufacturing remains particularly weak in high-value segments such as diagnostics, vaccines, biopharmaceuticals and medical devices, despite the significant market opportunities in these areas.
Nigeria, however, recorded its first local production of long-lasting insecticidal nets during the period, manufacturing two million nets in 2026, compared with none in 2025, according to the 2026 Joint Annual Review of the Health sector report published in November
The local production met an estimated 6 percent of national requirements, following the commissioning of two local manufacturing facilities.
Also, the number of products transitioned from importation to local production increased from 49 in 2025 to 51 in 2026, while Nigeria had 190 local pharmaceutical manufacturing companies, according to the report.
While local manufacturers and other players in the pharmaceutical sector have commended the potential of the incentives to stimulate local production, they have also highlighted implementation delays, bureaucratic bottlenecks and persistently high operating costs as hurdles to the Executive Order’s effectiveness.
A study by the National Institute for Pharmaceutical Research and Development (NIPRD) on the implementation and impact of the Executive Order found that fewer than 40 percent of surveyed manufacturers reported tangible improvements in production capacity, innovation or investment.
Although awareness of the policy was high at 92.1 percent, only 53.1 percent of respondents had attended policy-related seminars or training. Excessive bureaucracy was identified as a major implementation barrier by 71.9 percent, while 70.3 percent cited inadequate training.
Consequently, Nigeria is missing out on a significant market opportunity. The report estimates the healthcare products market at between $4 billion and $6 billion. Therapeutic pharmaceuticals represent the largest market segment, valued at $1.7 billion to $2.2 billion. Yet local manufacturers supply only 15 to 35 percent of demand.
Non-therapeutic consumer health products, valued at $1.1 billion to $1.3 billion, have a similar local production share of 15 to 35 percent. Local production accounts for just 0 to 2 percent of diagnostics, while domestic production of biopharmaceuticals, including vaccines, and medical devices is estimated at zero percent.
Animal health products have a local production share of just 2 to 5 percent, while medical consumables and equipment have a limited domestic production share of 15 to 35 percent.
A local pharmaceutical manufacturer, Chimezie Amadi, owner of Soha Pharmaceuticals, Lugbe, said medicine prices had not fallen, although some products had remained relatively stable over the past year, while others had increased.
“For instance, Emzor paracetamol has been N300 per card for a year now. It used to be less. So prices have not reduced; some are stable, while others are increasing.”
A market survey showed that amoxicillin, an antibiotic used to treat bacterial infections, increased in price from between N1,500 and N2,000 in 2025 to N17,655 in 2026.
Metformin, commonly prescribed to people with type 2 diabetes to control blood sugar levels, rose from N500 in 2024 to N9,795 as of November 2026, while amlodipine, used to treat high blood pressure and certain heart-related conditions, increased from N1,800 to N3,030.
Artemether-lumefantrine, a combination medicine used to treat uncomplicated malaria, had a median price of N3,615 in November 2026, compared with a 2024 price range of N1,200 to N3,800.
However, the tax incentives have generated savings for some manufacturers. Lanre Shittu, chairman of HMA Medicals Limited, said his company saved hundreds of millions of naira through the import duty and tax waivers.
“The policy is beneficial, but its impact would depend on continuity and improvements in implementation,” he said.
Manufacturers, he said, still face high operating costs, expensive energy, double-digit interest rates and limited access to loans and capital.
Andrew Chimezie of DCL Laboratories also said the policy was beneficial but urged the government to remove bureaucratic bottlenecks, particularly in clearing imported production inputs.
Some manufacturers have also reported improved financial performance. Neimeth International Pharmaceuticals Plc said the incentives helped reduce production costs and support its return to profitability in 2025. Fidson Healthcare Plc also reported a 61 percent increase in profit after tax to N9.31 billion in 2025.
Manufacturers are now asking the Federal Government to sustain the incentives to give the industry more time to expand production and deepen investment.
Oluwatosin Jolayemi, chairman of the Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria, said the current policy window should be extended to enable manufacturers to expand production capacity and consolidate gains.
He said the industry needed policy consistency and a predictable investment environment to overcome persistent challenges, including high energy and production costs, supply chain disruptions, port inefficiencies, limited access to long-term capital and market access constraints.




